Nivolumab Overview

Introduction of Nivolumab

Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a human immunoglobulin G4 (IgG4) monoclonal antibody (mAb). The gamma 1 heavy chain is 91.8% unmodified human design while the kappa light chain is 98.9%. It is the first-in-human programmed death-1 (PD-1) immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), thereby inhibiting the cellular immune response. Nivolumab was created by scientists at Medarex using Medarex's transgenic mice with a humanized immune system. Medarex licensed Japanese rights to nivolumab to Ono Pharmaceutical in 2005. Bristol-Myers Squibb acquired Medarex in 2009. Ono received approval from Japanese regulatory authorities to use nivolumab to treat unresectable melanoma in July 2014, which was the first regulatory approval of a PD-1 inhibitor anywhere in the world. Nivolumab received Food and Drug Administration (FDA) approval for the treatment of melanoma in December 2014. In April 2015, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Nivolumab for metastatic melanoma as a monotherapy. In March 2015, the US FDA approved it for the treatment of squamous cell lung cancer (SCLC). On 19 June 2015 the European Commission granted a marketing authorization valid throughout the European Union. In November 2015, the FDA approved nivolumab as a second-line treatment for renal cell carcinoma (RCC) after having granted the application breakthrough therapy designation, fast track designation, and priority review status. In May 2016, the FDA approved nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin. On December 20, 2017, the FDA granted approval to nivolumab for adjuvant treatment of melanoma with involvement of lymph nodes or for metastatic disease with complete resection. On April 16, 2018, the FDA granted approval to nivolumab in combination with ipilimumab for the first-line treatment of intermediate and poor risk advanced RCC patients. Side effects include severe immune-related inflammation of the lungs, colon, liver, kidneys, and thyroid, and there are effects on skin, central nervous system, the heart, and the digestive system.

Mechanism of Action of Nivolumab

PD-1 is a member of the CD28 family of T-cell receptors, and is primarily expressed on activated T cells, B cells and myeloid cells. PD-1 is upregulated on T cells after chronic antigen stimulation, and is a marker of T-cell exhaustion. Key ligands for PD-1 include PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed by immune cells, and can also be induced on a variety of tissues, particularly after exposure to inflammatory cytokines, such as IFN-γ. PD-L1 is expressed on a variety of human cancers, and this expression is thought to play an important role in evading antitumor immune responses. Human tumors have also been documented to express PD-L2, although its role is less clear. When PD-1 on T cells binds PD-L1 or PD-L2, the T cell receives an inhibitory signal and no longer mounts productive immune responses. Nivolumab blocks PD-L1 from binding to PD-1, allowing the T cell to work.

> Mechanism of action of nivolumabFig.1 Mechanism of action of nivolumab

Table 1. Clinical Projects of Nivolumab*

NCT ID Status Conditions Lead Sponsor Update Time
NCT03343665 Recruiting Hodgkin Lymphoma St. Petersburg State Pavlov Medical University November 17, 2017
NCT03630640 Not yet recruiting Hepatocellular Carcinoma Assistance Publique - Hôpitaux de Paris August 15, 2018
NCT03452579 Recruiting Glioblastoma Case Comprehensive Cancer Center March 2, 2018
NCT03136627 Active, not recruiting Carcinoma, Renal Cell AVEO Pharmaceuticals, Inc. May 2, 2017
NCT03544736 Recruiting Esophageal Cancer Oslo University Hospital June 4, 2018
NCT02799901 Recruiting Melanoma Centre Hospitalier Universitaire de Nice June 15, 2016
NCT03542461 Recruiting Squamous Non-small Cell Lung Cancer Gruppo Oncologico Italiano di Ricerca Clinica May 31, 2018
NCT03353675 Recruiting NSCLC Transgene November 27, 2017
NCT03406871 Recruiting Advanced and Metastatic Solid Tumor Kohei Shitara January 23, 2018
NCT03184194 Recruiting Myeloma VU University Medical Center June 12, 2017
NCT03172624 Recruiting Salivary Gland Cancer Memorial Sloan Kettering Cancer Center June 1, 2017
NCT03126331 Recruiting Metastatic Renal Cell Carcinoma Case Comprehensive Cancer Center April 24, 2017
NCT03586999 Not yet recruiting Peripheral T Cell Lymphoma University of Colorado, Denver July 16, 2018
NCT03436862 Recruiting Hodgkin Lymphoma SCRI Development Innovations, LLC February 19, 2018
NCT03635892 Recruiting Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center August 17, 2018
NCT03564197 Not yet recruiting NSCLC Stage IV The Netherlands Cancer Institute June 20, 2018
NCT03282344 Recruiting SARCOMA Memorial Sloan Kettering Cancer Center September 13, 2017
NCT03143270 Recruiting Liver Cancer Memorial Sloan Kettering Cancer Center May 8, 2017
NCT03635983 Recruiting Melanoma Bristol-Myers Squibb August 17, 2018
NCT03343652 Recruiting Hodgkin's Lymphoma St. Petersburg State Pavlov Medical University November 17, 2017
NCT03292263 Recruiting Multiple Myeloma St. Petersburg State Pavlov Medical University September 25, 2017
NCT02768558 Active, not recruiting Non-Small Cell Lung Cancer RTOG Foundation, Inc. May 11, 2016
NCT02764593 Active, not recruiting Head and Neck Squamous Cell Carcinoma (HNSCC) RTOG Foundation, Inc. May 6, 2016
NCT03225365 Not yet recruiting Metastatic Melanoma Hospices Civils de Lyon July 21, 2017
NCT03241186 Recruiting Mucosal Melanoma Robert R. McWilliams, MD August 7, 2017
NCT02460068 Recruiting Brain Metastases Italian Network for Tumor Biotherapy Foundation June 2, 2015
NCT02684253 Recruiting Head and Neck Squamous Cell Carcinoma (HNSCC) Memorial Sloan Kettering Cancer Center February 17, 2016
NCT03325257 Recruiting Melanoma Nantes University Hospital October 30, 2017
NCT03013335 Recruiting Metastatic Renal Cell Carcinoma UNICANCER January 6, 2017
NCT02716272 Active, not recruiting Mesothelioma Intergroupe Francophone de Cancerologie Thoracique March 23, 2016
NCT03117309 Recruiting Advanced Renal Cell Carcinoma Michael B. Atkins, MD April 17, 2017
NCT03532451 Not yet recruiting Bladder Cancer PrECOG, LLC. May 22, 2018
NCT03297593 Recruiting Renal Cell Carcinoma Swiss Group for Clinical Cancer Research September 29, 2017
NCT03259516 Recruiting Myelodysplastic Syndromes St. Petersburg State Pavlov Medical University August 23, 2017
NCT03520491 Recruiting Bladder Cancer Memorial Sloan Kettering Cancer Center May 9, 2018
NCT03026140 Recruiting Colon Carcinoma The Netherlands Cancer Institute January 20, 2017
NCT03692338 Not yet recruiting Metastatic Renal Cell Carcinoma Duke University October 2, 2018
NCT02426892 Active, not recruiting Solid Tumors M.D. Anderson Cancer Center April 27, 2015
NCT03122522 Recruiting Metastatic Melanoma Memorial Sloan Kettering Cancer Center April 20, 2017
NCT02329847 Active, not recruiting Hematologic Neoplasms Janssen Research & Development, LLC January 1, 2015
NCT02812667 Recruiting Non-small Cell Lung Cancer Metastatic Lyudmila Bazhenova, M.D. June 24, 2016
NCT02599649 Active, not recruiting Leukemia M.D. Anderson Cancer Center November 6, 2015
NCT03547999 Recruiting Metastatic Colorectal Cancer Darren Carpizo, MD June 6, 2018
NCT03259529 Recruiting Diffuse Large B Cell Lymphoma St. Petersburg State Pavlov Medical University August 23, 2017
NCT03451331 Recruiting Metastatic Urothelial Cancer Matthew Galsky March 1, 2018
NCT02350764 Recruiting Advanced Stage Non-small Cell Lung Cancer Memorial Sloan Kettering Cancer Center January 30, 2015
NCT02731729 Active, not recruiting Melanoma Parker Institute for Cancer Immunotherapy April 7, 2016
NCT03033914 Recruiting Hodgkin Lymphoma Memorial Sloan Kettering Cancer Center January 27, 2017
NCT03026166 Active, not recruiting Small Cell Lung Cancer AbbVie January 20, 2017
NCT02910700 Recruiting Melanoma M.D. Anderson Cancer Center September 22, 2016
NCT03004833 Recruiting Classical Hodgkin Lymphoma University of Cologne December 29, 2016
NCT03040791 Recruiting Prostate Cancer Hospital Moinhos de Vento February 2, 2017
NCT02859324 Active, not recruiting Carcinoma, Hepatocellular Celgene August 9, 2016
NCT02696993 Recruiting Metastatic Brain Cancer M.D. Anderson Cancer Center March 2, 2016
NCT03510871 Not yet recruiting Hepatocellular Carcinoma (HCC) National Health Research Institutes, Taiwan April 27, 2018
NCT03369223 Recruiting Advanced Cancer Bristol-Myers Squibb December 11, 2017
NCT03639935 Not yet recruiting Biliary Tract Cancer University of Michigan Cancer Center August 21, 2018
NCT03214250 Recruiting Metastatic Pancreatic Adenocarcinoma Parker Institute for Cancer Immunotherapy July 11, 2017
NCT03061539 Recruiting Prostate Cancer University College, London February 23, 2017
NCT03680521 Recruiting Clear Cell Renal Cell Carcinoma Mirati Therapeutics Inc. September 21, 2018
NCT02437279 Active, not recruiting Stage III Skin Melanoma The Netherlands Cancer Institute May 7, 2015
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel October 5, 2018
NCT02901145 Not yet recruiting Antibodies, Neoplasm Hadassah Medical Organization September 15, 2016
NCT03267498 Recruiting Nasopharyngeal Carcinoma University of California, San Francisco August 30, 2017
NCT03521830 Not yet recruiting Basal Cell Carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins May 10, 2018
NCT03246958 Recruiting Thyroid Cancer Dana-Farber Cancer Institute August 11, 2017
NCT03469713 Recruiting Renal Cancer Metastatic Gruppo Oncologico Italiano di Ricerca Clinica March 19, 2018
NCT03219671 Not yet recruiting Classic Kaposi Sarcoma Alona Zer July 17, 2017
NCT03226756 Not yet recruiting Recurrent and/or Metastatic Platinum-refractory SCCHN UNICANCER July 24, 2017
NCT03637543 Not yet recruiting Prostate Cancer Beth Israel Deaconess Medical Center August 20, 2018
NCT03390738 Not yet recruiting Nasopharyngeal Carcinoma The University of Hong Kong January 4, 2018
NCT03681561 Recruiting Hodgkin Lymphoma Veronika Bachanova September 24, 2018
NCT02939300 Recruiting Leptomeningeal Carcinomatosis Massachusetts General Hospital October 20, 2016
NCT03557359 Recruiting Gliomas Columbia University June 15, 2018
NCT03347123 Recruiting Solid Tumors Incyte Corporation November 20, 2017
NCT03405155 Recruiting Melanoma (Skin) Sidney Kimmel Cancer Center at Thomas Jefferson University January 19, 2018
NCT03245021 Recruiting Follicular Lymphoma Dr. Eliza Hawkes August 10, 2017
NCT03299946 Recruiting Locally Advanced Hepatocellular Carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins October 3, 2017
NCT03190265 Recruiting Pancreatic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins June 16, 2017
NCT03250273 Recruiting Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreactic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins August 15, 2017
NCT03341936 Recruiting Squamous Cell Carcinoma of the Head and Neck Dana-Farber Cancer Institute November 14, 2017
NCT03294304 Recruiting Muscle Invasive Bladder Cancer Masonic Cancer Center, University of Minnesota September 27, 2017
NCT03599362 Recruiting Pancreatic Cancer New York University School of Medicine July 25, 2018
NCT03161379 Recruiting Pancreatic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins May 19, 2017
NCT02259621 Recruiting Non-Small Cell Lung Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins October 8, 2014
NCT02944396 Active, not recruiting Non-Small Cell Lung Cancer AbbVie October 25, 2016
NCT03172754 Recruiting Renal Cell Carcinoma Fox Chase Cancer Center June 1, 2017
NCT03382886 Recruiting Hepatocellular Carcinoma University of Utah December 26, 2017
NCT03472586 Recruiting Eye and Orbit Sidney Kimmel Cancer Center at Thomas Jefferson University March 21, 2018
NCT03692325 Not yet recruiting Leukoplakia, Oral Dana-Farber Cancer Institute October 2, 2018
NCT03502746 Recruiting Mesothelioma, Malignant Arkadiusz Z. Dudek, MD April 19, 2018
NCT02781506 Recruiting Metastatic Clear Cell Renal Cell Carcinoma University of Texas Southwestern Medical Center May 24, 2016
NCT03374839 Recruiting Melanoma Nantes University Hospital December 15, 2017
NCT03461952 Not yet recruiting Advanced Solid Tumors Canadian Cancer Trials Group March 12, 2018
NCT03171025 Recruiting Bladder Cancer University of Utah May 31, 2017
NCT02933255 Recruiting Prostate Cancer National Cancer Institute (NCI) October 14, 2016
NCT03146468 Recruiting Haematological Malignancy Melbourne Health May 10, 2017
NCT03563248 Recruiting Pancreatic Cancer Massachusetts General Hospital June 20, 2018
NCT02499367 Recruiting Breast Cancer The Netherlands Cancer Institute July 16, 2015
NCT03366272 Recruiting Lymphoma, Non-Hodgkin University Hospital, Saarland December 8, 2017
NCT03404960 Recruiting Pancreatic Adenocarcinoma University of Pennsylvania January 19, 2018
NCT02919683 Recruiting Head and Neck Cancer Dana-Farber Cancer Institute September 29, 2016
NCT03047928 Recruiting Metastatic Melanoma Inge Marie Svane February 9, 2017
NCT03418922 Recruiting Carcinoma, Hepatocellular Eisai Co., Ltd. February 1, 2018
NCT02323126 Recruiting Non Small Cell Lung Cancer Novartis Pharmaceuticals December 23, 2014
NCT02989636 Recruiting Chordoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins December 12, 2016
NCT03414684 Recruiting Breast Cancer Dana-Farber Cancer Institute January 30, 2018
NCT03646617 Recruiting Metastatic Melanoma Abramson Cancer Center of the University of Pennsylvania August 24, 2018
NCT02940301 Recruiting Classical Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center October 20, 2016
NCT03091491 Recruiting Non-Small Cell Lung Cancer National Cancer Centre, Singapore March 27, 2017
NCT03113188 Recruiting Advanced Solid Tumors CanBas Co. Ltd. April 13, 2017
NCT02948348 Recruiting Cancer of Rectum Takayuki Yoshino October 28, 2016
NCT03656718 Recruiting Neoplasms by Site Bristol-Myers Squibb September 3, 2018
NCT03600350 Recruiting Prostate Cancer University of Wisconsin, Madison July 25, 2018
NCT03480334 Not yet recruiting Classical Hodgkin Lymphoma University of Cologne March 29, 2018
NCT03097939 Recruiting Nasopharyngeal Carcinoma National Cancer Centre, Singapore March 31, 2017
NCT03048474 Active, not recruiting Malignant Pleural Mesothelioma The Netherlands Cancer Institute February 9, 2017
NCT02648997 Recruiting Meningiomas Dana-Farber Cancer Institute January 7, 2016
NCT03021993 Recruiting Oral Cavity SCC David Neskey January 16, 2017
NCT03355560 Recruiting Head and Neck Cancer Trisha Wise-Draper November 28, 2017
NCT03311958 Recruiting Diffuse Large B Cell Lymphoma Fox Chase Cancer Center October 17, 2017
NCT02970981 Active, not recruiting Melanoma New York University School of Medicine November 22, 2016
NCT03132493 Active, not recruiting Non Small Cell Lung Cancer Spanish Lung Cancer Group April 27, 2017
NCT03256136 Recruiting Lung Cancer Massachusetts General Hospital August 21, 2017
NCT03590210 Recruiting Metastatic Adult Soft Tissue Sarcoma University Medicine Greifswald July 18, 2018
NCT03528408 Recruiting Melanoma Suthee Rapisuwon May 17, 2018
NCT03651271 Not yet recruiting Advanced Metastatic Cancer Parker Institute for Cancer Immunotherapy August 29, 2018
NCT03278626 Recruiting Esophageal Squamous Cell Carcinoma New York University School of Medicine September 11, 2017
NCT03690986 Not yet recruiting Squamous Cell Carcinoma of the Head and Neck Emory University October 1, 2018
NCT03442569 Recruiting Colon Cancer UNC Lineberger Comprehensive Cancer Center February 22, 2018
NCT03316586 Recruiting Breast Cancer Dana-Farber Cancer Institute October 20, 2017
NCT03425331 Recruiting Non-small Cell Lung Cancer Dana-Farber Cancer Institute February 7, 2018
NCT02614456 Recruiting Advanced Solid Tumors Fox Chase Cancer Center November 25, 2015
NCT02880020 Recruiting Gastrointestinal Stromal Tumor Jonsson Comprehensive Cancer Center August 26, 2016
NCT03262779 Recruiting Carcinoma, Non-Small-Cell Lung Yale University August 25, 2017
NCT02181738 Active, not recruiting Hodgkin Disease Bristol-Myers Squibb July 4, 2014
NCT03181308 Recruiting Carcinoma, Non-Small-Cell Lung Tracon Pharmaceuticals Inc. June 8, 2017
NCT02575222 Active, not recruiting Clear Cell Renal Cell Carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins October 14, 2015
NCT02923531 Active, not recruiting Clear Cell Renal Cell Carcinoma X4 Pharmaceuticals October 4, 2016
NCT03519308 Recruiting Pancreatic Cancer Abramson Cancer Center of the University of Pennsylvania May 8, 2018
NCT03400332 Recruiting Cancer Bristol-Myers Squibb January 17, 2018
NCT02832167 Recruiting Cancer Bristol-Myers Squibb July 14, 2016
NCT02960906 Recruiting Clear Cell Metastatic Renal Cell Carcinoma Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie November 10, 2016
NCT03195478 Recruiting Solid Tumor Bristol-Myers Squibb June 22, 2017
NCT02856451 Active, not recruiting Encephalitis Bristol-Myers Squibb August 4, 2016
NCT03233152 Recruiting Glioblastoma Universitair Ziekenhuis Brussel July 28, 2017
NCT03527108 Not yet recruiting Non Small Cell Lung Cancer Fox Chase Cancer Center May 16, 2018
NCT03486119 Recruiting Non -Small Cell Lung Cancer Yonsei University April 3, 2018
NCT02599402 Active, not recruiting Melanoma Bristol-Myers Squibb November 6, 2015
NCT03381118 Recruiting Acute Myeloid Leukemia St. Petersburg State Pavlov Medical University December 21, 2017
NCT03558087 Recruiting Bladder Cancer Matthew Galsky June 15, 2018
NCT02659059 Active, not recruiting Non-Small-Cell Lung Cancer Bristol-Myers Squibb January 20, 2016
NCT02983006 Recruiting Melanoma New York University School of Medicine December 6, 2016
NCT03192943 Active, not recruiting Advanced Cancer Bristol-Myers Squibb June 20, 2017
NCT03259425 Recruiting Melanoma University of Utah August 23, 2017
NCT02038946 Active, not recruiting Lymphoma Bristol-Myers Squibb January 17, 2014
NCT03663166 Not yet recruiting Carcinoma, Non-Small-Cell Lung H. Lee Moffitt Cancer Center and Research Institute September 10, 2018
NCT03203473 Recruiting Renal Cancer Dana-Farber Cancer Institute June 29, 2017
NCT03430791 Not yet recruiting Recurrent Glioblastoma Baptist Health South Florida February 13, 2018
NCT02626962 Active, not recruiting Uveal Melanoma Grupo Español Multidisciplinar de Melanoma December 10, 2015
NCT02523469 Recruiting Non-small Cell Lung Cancer Medical University of South Carolina August 14, 2015
NCT03215706 Recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb July 12, 2017
NCT03700905 Recruiting Head and Neck Cancer Universitätsklinikum Hamburg-Eppendorf October 9, 2018
NCT03470922 Recruiting Melanoma Bristol-Myers Squibb March 20, 2018
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili June 11, 2018
NCT03597282 Recruiting Metastatic Melanoma Neon Therapeutics, Inc. July 24, 2018
NCT03158272 Recruiting Advanced Malignancies Bristol-Myers Squibb May 18, 2017
NCT02434081 Active, not recruiting Non-small Cell Lung Cancer Stage III European Thoracic Oncology Platform May 5, 2015
NCT03033446 Recruiting HepatoCellular Carcinoma National Cancer Centre, Singapore January 26, 2017
NCT03661632 Recruiting Advanced Cancer Bristol-Myers Squibb September 7, 2018
NCT03532217 Recruiting Metastatic Hormone-Sensitive Prostate Cancer Washington University School of Medicine May 22, 2018
NCT02989714 Recruiting Renal Cell Carcinoma University of Michigan Cancer Center December 12, 2016
NCT03495713 Recruiting Hodgkin Lymphoma Abramson Cancer Center of the University of Pennsylvania April 12, 2018
NCT03349710 Recruiting Squamous Cell Carcinoma of the Head and Neck Bristol-Myers Squibb November 21, 2017
NCT02985957 Active, not recruiting Prostate Cancer Bristol-Myers Squibb December 7, 2016
NCT03576417 Not yet recruiting Squamous Cell Carcinoma of Head and Neck Groupe Oncologie Radiotherapie Tete et Cou July 3, 2018
NCT03636477 Recruiting Glioblastoma Ziopharm August 17, 2018
NCT03521570 Recruiting Recurrent Head and Neck Squamous Cell Carcinoma Emory University May 10, 2018
NCT03396211 Recruiting Cancer LSK BioPartners Inc. January 10, 2018
NCT02275533 Recruiting Acute Myeloid Leukemia in Remission National Cancer Institute (NCI) October 27, 2014
NCT02387996 Active, not recruiting Various Advanced Cancer Bristol-Myers Squibb March 13, 2015
NCT03101566 Recruiting Biliary Tract Neoplasms University of Michigan Cancer Center April 5, 2017
NCT02968303 Recruiting Melanoma, Malignant, of Soft Parts Radboud University November 18, 2016
NCT03446040 Recruiting Advanced Cancer Bristol-Myers Squibb February 26, 2018
NCT02574078 Active, not recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb October 12, 2015
NCT03090737 Recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb March 27, 2017
NCT02869789 Recruiting Lung Cancer Bristol-Myers Squibb August 17, 2016
NCT03363776 Recruiting Cancer Bristol-Myers Squibb December 6, 2017
NCT02940639 Recruiting Renal Cell Carcinoma Bristol-Myers Squibb October 21, 2016
NCT03546686 Not yet recruiting Breast Cancer Cedars-Sinai Medical Center June 5, 2018
NCT03141177 Recruiting Renal Cell Carcinoma Bristol-Myers Squibb May 4, 2017
NCT03110107 Recruiting Advanced Cancer Bristol-Myers Squibb April 12, 2017
NCT02446860 Recruiting Renal Cell Carcinoma Royal Marsden NHS Foundation Trust May 18, 2015
NCT01783938 Active, not recruiting Advanced or Metastatic Melanoma Bristol-Myers Squibb February 5, 2013
NCT03655444 Not yet recruiting Head and Neck Squamous Cell Carcinoma Washington University School of Medicine August 31, 2018
NCT02954991 Recruiting Carcinoma, Non-Small-Cell Lung Mirati Therapeutics Inc. November 4, 2016
NCT03668119 Not yet recruiting Pan Tumor Bristol-Myers Squibb September 12, 2018
NCT03336216 Recruiting Advanced Pancreatic Cancer Bristol-Myers Squibb November 8, 2017
NCT02922764 Recruiting Malignant Neoplasms Rgenix, Inc. October 4, 2016
NCT02754141 Recruiting Malignant Solid Tumor Bristol-Myers Squibb April 28, 2016
NCT02899299 Active, not recruiting Mesothelioma Bristol-Myers Squibb September 14, 2016
NCT02829931 Recruiting Malignant Glioma H. Lee Moffitt Cancer Center and Research Institute July 12, 2016
NCT03338790 Recruiting Prostate Cancer Bristol-Myers Squibb November 9, 2017
NCT02572167 Active, not recruiting Hodgkin Lymphoma Seattle Genetics, Inc. October 8, 2015
NCT03496662 Recruiting Pancreatic Ductal Adenocarcinoma Washington University School of Medicine April 12, 2018
NCT02910999 Recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb September 22, 2016
NCT02966548 Recruiting Cancer Bristol-Myers Squibb November 17, 2016
NCT02628574 Recruiting Solid Tumors Leap Therapeutics, Inc. December 11, 2015
NCT02635061 Recruiting Non Small Cell Lung Cancer Celgene December 18, 2015
NCT03382561 Recruiting Extensive Stage Small Cell Lung Carcinoma National Cancer Institute (NCI) December 26, 2017
NCT03273790 Active, not recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb September 6, 2017
NCT03509584 Not yet recruiting Non-small Cell Lung Cancer Assistance Publique Hopitaux De Marseille April 26, 2018
NCT03301636 Recruiting Melanoma NewLink Genetics Corporation October 4, 2017
NCT02905266 Active, not recruiting Melanoma Bristol-Myers Squibb September 19, 2016
NCT03380130 Recruiting Hepatocellular Carcinoma Clinica Universidad de Navarra, Universidad de Navarra December 20, 2017
NCT03114163 Recruiting Head and Neck Cancer Bristol-Myers Squibb April 14, 2017
NCT03444753 Recruiting Advanced Cancer Bristol-Myers Squibb February 23, 2018
NCT02726581 Active, not recruiting Multiple Myeloma Bristol-Myers Squibb April 1, 2016
NCT02105636 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck Bristol-Myers Squibb April 7, 2014
NCT02243371 Active, not recruiting Previously Treated Metastatic Adenocarcinoma of the Pancreas Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins September 17, 2014
NCT03029780 Active, not recruiting Renal Cell Carcinoma Bristol-Myers Squibb January 24, 2017
NCT01928394 Active, not recruiting Advanced or Metastatic Solid Tumors Bristol-Myers Squibb August 23, 2013
NCT02857426 Recruiting Lymphoma Bristol-Myers Squibb August 5, 2016
NCT03382912 Recruiting Non Small Cell Lung Cancer ARMO BioSciences December 26, 2017
NCT03565406 Recruiting Melanoma New York University School of Medicine June 21, 2018
NCT03200977 Recruiting Lymphoma Bristol-Myers Squibb June 27, 2017
NCT02998528 Recruiting Non Small Cell Lung Cancer Bristol-Myers Squibb December 20, 2016
NCT02481830 Active, not recruiting Lung Cancer Bristol-Myers Squibb June 25, 2015
NCT03100006 Recruiting Epithelial Ovarian Cancer National Cancer Centre, Singapore April 4, 2017
NCT03414983 Recruiting Colorectal Cancer Bristol-Myers Squibb January 30, 2018
NCT02476123 Active, not recruiting Solid Tumor Kyowa Hakko Kirin Co., Ltd June 19, 2015
NCT02985554 Recruiting Hematologic Malignancies University of Chicago December 7, 2016
NCT03132675 Recruiting Stage III/IV Melanoma OncoSec Medical Incorporated April 28, 2017
NCT03382496 Active, not recruiting Lung Cancer Bristol-Myers Squibb December 26, 2017
NCT03075423 Recruiting Metastatic Renal Cell Carcinoma Nicola Goekbuget March 9, 2017
NCT03569696 Not yet recruiting Lymphoma, B-Cell Meirav Kedmi MD June 26, 2018
NCT02743494 Recruiting Advanced Cancer Bristol-Myers Squibb April 19, 2016
NCT03138512 Recruiting Renal Cell Carcinoma Bristol-Myers Squibb May 3, 2017
NCT03130959 Recruiting Various Advanced Cancer Bristol-Myers Squibb April 27, 2017
NCT02857569 Recruiting Stage III/IV Melanoma Gustave Roussy, Cancer Campus, Grand Paris August 5, 2016
NCT02596035 Active, not recruiting Renal Cell Carcinoma Bristol-Myers Squibb November 4, 2015
NCT02982954 Active, not recruiting Renal Cell Carcinoma Bristol-Myers Squibb December 6, 2016
NCT02823574 Active, not recruiting Head and Neck Cancer Bristol-Myers Squibb July 6, 2016
NCT02613507 Active, not recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb November 24, 2015
NCT02990611 Recruiting Melanoma Bristol-Myers Squibb December 13, 2016
NCT02913313 Recruiting Broad Solid Tumor Bristol-Myers Squibb September 23, 2016
NCT02737475 Recruiting Advanced Cancer Bristol-Myers Squibb April 14, 2016
NCT03692442 Recruiting Lung Cancer Non-small Cell Stage IV Guangzhou Institute of Respiratory Disease October 2, 2018
NCT01668784 Active, not recruiting Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma Bristol-Myers Squibb August 20, 2012
NCT03036098 Recruiting Urothelial Cancer Bristol-Myers Squibb January 30, 2017
NCT03001882 Recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb December 23, 2016
NCT03098550 Active, not recruiting Advanced Cancer Bristol-Myers Squibb March 31, 2017
NCT03351361 Not yet recruiting Advanced Non Small Cell Lung Cancer Rennes University Hospital November 22, 2017
NCT01673867 Active, not recruiting Non-Squamous Cell Non-small Cell Lung Cancer Bristol-Myers Squibb August 28, 2012
NCT03670056 Not yet recruiting Small Cell Lung Cancer Yale University September 13, 2018
NCT03406247 Not yet recruiting Head and Neck Squamous Cell Carcinoma Gustave Roussy, Cancer Campus, Grand Paris January 23, 2018
NCT03068455 Active, not recruiting Melanoma Bristol-Myers Squibb March 1, 2017
NCT02700971 Recruiting Metastatic Melanoma AHS Cancer Control Alberta March 7, 2016
NCT01721759 Active, not recruiting Squamous Cell Non-small Cell Lung Cancer Bristol-Myers Squibb November 6, 2012
NCT02393625 Recruiting ALK-positive NSCLC Novartis Pharmaceuticals March 19, 2015
NCT02593786 Recruiting Solid Tumors Bristol-Myers Squibb November 2, 2015
NCT02488759 Recruiting Various Advanced Cancer Bristol-Myers Squibb July 2, 2015
NCT03562507 Not yet recruiting Renal Cell Carcinoma, Metastatic University of Michigan Cancer Center June 19, 2018
NCT02451982 Recruiting Pancreatic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins May 22, 2015
NCT02576509 Active, not recruiting Hepatocellular Carcinoma Bristol-Myers Squibb October 15, 2015
NCT02741570 Recruiting Head and Neck Cancer Bristol-Myers Squibb April 18, 2016
NCT03203876 Active, not recruiting Advanced Cancer Bristol-Myers Squibb June 29, 2017
NCT01844505 Active, not recruiting Unresectable or Metastatic Melanoma Bristol-Myers Squibb May 1, 2013
NCT02714218 Active, not recruiting Melanoma Bristol-Myers Squibb March 21, 2016
NCT02864251 Recruiting Non-Small-Cell Lung Carcinoma Bristol-Myers Squibb August 11, 2016
NCT03591731 Not yet recruiting Neuroendocrine Carcinoma Intergroupe Francophone de Cancerologie Thoracique July 19, 2018
NCT03703050 Recruiting Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma Gustave Roussy, Cancer Campus, Grand Paris October 11, 2018
NCT02632409 Recruiting Various Advanced Cancer Bristol-Myers Squibb December 16, 2015
NCT02017717 Active, not recruiting Recurrent Glioblastoma Bristol-Myers Squibb December 23, 2013
NCT02388906 Active, not recruiting Melanoma Bristol-Myers Squibb March 17, 2015
NCT02523313 Recruiting Malignant Melanoma Prof. Dr. med. Dirk Schadendorf August 14, 2015
NCT03143153 Recruiting Various Advanced Cancer Bristol-Myers Squibb May 8, 2017
NCT03371381 Active, not recruiting Adenocarcinoma of Lung Janssen Research & Development, LLC December 13, 2017
NCT02667587 Recruiting Brain Neoplasms Bristol-Myers Squibb January 29, 2016
NCT02581631 Recruiting Non-Hodgkin's Disease Bristol-Myers Squibb October 21, 2015
NCT02066636 Active, not recruiting Non Small Cell Lung Cancer (NSCLC) Bristol-Myers Squibb February 19, 2014
NCT03228667 Recruiting Non-Small Cell Lung Cancer Altor BioScience July 25, 2017
NCT02927769 Recruiting Hodgkin Disease Bristol-Myers Squibb October 7, 2016
NCT02598960 Active, not recruiting Solid Tumors Bristol-Myers Squibb November 6, 2015
NCT03138499 Recruiting Hodgkin's Disease Bristol-Myers Squibb May 3, 2017
NCT03071094 Recruiting Hepatocellular Carcinoma (HCC) Transgene March 6, 2017
NCT03682276 Not yet recruiting Hepatocellular Carcinoma Imperial College London September 24, 2018
NCT02011945 Active, not recruiting Chronic Myeloid Leukemia Bristol-Myers Squibb December 16, 2013
NCT02959554 Recruiting Metastatic Renal Cell Carcinoma AIO-Studien-gGmbH November 9, 2016
NCT02041533 Active, not recruiting Stage IV or Recurrent Non-Small Cell Lung Cancer Bristol-Myers Squibb January 22, 2014
NCT01642004 Active, not recruiting Squamous Cell Non-small Cell Lung Cancer Bristol-Myers Squibb July 17, 2012
NCT02038933 Active, not recruiting Lymphoma. Non-Hodgkin Bristol-Myers Squibb January 17, 2014
NCT01714739 Active, not recruiting CANCER,NOS Bristol-Myers Squibb October 26, 2012
NCT02320058 Active, not recruiting Melanoma Bristol-Myers Squibb December 19, 2014
NCT03161613 Recruiting Multiple Indications Cancer Bristol-Myers Squibb May 22, 2017
NCT02612779 Active, not recruiting Multiple Myeloma Bristol-Myers Squibb November 24, 2015
NCT02617589 Recruiting Brain Cancer Bristol-Myers Squibb December 1, 2015
NCT03337919 Not yet recruiting Hodgkin Lymphoma University College, London November 9, 2017
NCT02713867 Active, not recruiting Lung Cancer Bristol-Myers Squibb March 21, 2016
NCT02477826 Recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb June 23, 2015
NCT03350126 Recruiting Metastatic Cancer Colorectal GERCOR - Multidisciplinary Oncology Cooperative Group November 22, 2017
NCT02582125 Active, not recruiting Advanced Non-small Cell Lung Cancer Ono Pharmaceutical Co. Ltd October 21, 2015
NCT01454102 Active, not recruiting Non-small Cell Lung Cancer Bristol-Myers Squibb October 18, 2011
NCT02156804 Active, not recruiting Melanoma Bristol-Myers Squibb June 5, 2014
NCT02409368 Active, not recruiting Non-Small Cell Lung Cancer Bristol-Myers Squibb April 6, 2015
NCT02538666 Active, not recruiting Lung Cancer Bristol-Myers Squibb September 2, 2015
NCT01658878 Active, not recruiting Hepatocellular Carcinoma Bristol-Myers Squibb August 7, 2012
NCT02175017 Active, not recruiting Advanced Non-small Cell Lung Cancer Ono Pharmaceutical Co. Ltd June 26, 2014
NCT01176474 Active, not recruiting Melanoma (Skin) H. Lee Moffitt Cancer Center and Research Institute August 6, 2010
NCT03527264 Not yet recruiting Cervical Cancer Don Dizon May 17, 2018
NCT02569242 Active, not recruiting Esophageal Cancer Ono Pharmaceutical Co. Ltd October 6, 2015
NCT01721772 Active, not recruiting Melanoma Bristol-Myers Squibb November 6, 2012
NCT01721746 Active, not recruiting Unresectable or Metastatic Melanoma Bristol-Myers Squibb November 6, 2012
NCT02746796 Active, not recruiting Gastric Cancer Ono Pharmaceutical Co. Ltd April 21, 2016
NCT03437200 Not yet recruiting Inoperable œsophageal Cancer European Organisation for Research and Treatment of Cancer - EORTC February 19, 2018
NCT02267343 Active, not recruiting Gastric Cancer Ono Pharmaceutical Co. Ltd October 17, 2014
NCT03155061 Recruiting Advanced or Metastatic Solid Tumors Ono Pharmaceutical Co. Ltd May 16, 2017
NCT01354431 Active, not recruiting Renal Cell Carcinoma Bristol-Myers Squibb May 16, 2011
NCT01358721 Active, not recruiting Renal Cell Carcinoma Bristol-Myers Squibb May 24, 2011
NCT01176461 Active, not recruiting Melanoma (Skin) H. Lee Moffitt Cancer Center and Research Institute August 6, 2010
NCT01024231 Active, not recruiting Malignant Melanoma Bristol-Myers Squibb December 2, 2009
NCT03006705 Recruiting Gastric Cancer Ono Pharmaceutical Co. Ltd December 30, 2016
NCT03285321 Recruiting Non-small Cell Lung Cancer Greg Durm, MD September 18, 2017
NCT02659540 Active, not recruiting Melanoma Ludwig Institute for Cancer Research January 20, 2016
NCT02914405 Recruiting Neuroblastoma University Hospital Southampton NHS Foundation Trust September 26, 2016
NCT03223155 Recruiting Stage IV Small Cell Lung Cancer University of Chicago July 21, 2017
NCT02196961 Recruiting Merkel Cell Carcinoma Prof. Dr. med. Dirk Schadendorf July 22, 2014
NCT03203304 Recruiting Hepatocellular Carcinoma University of Chicago June 29, 2017
NCT03573947 Not yet recruiting Non-small Cell Lung Cancer Jeffrey Clarke June 29, 2018
NCT03525925 Recruiting Metastatic Malignant Solid Neoplasm Ohio State University Comprehensive Cancer Center May 16, 2018
NCT03576612 Active, not recruiting Glioma, Malignant Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 3, 2018
NCT02833233 Active, not recruiting Breast Cancer Memorial Sloan Kettering Cancer Center July 14, 2016
NCT03081689 Recruiting Non Small Cell Lung Cancer Spanish Lung Cancer Group March 16, 2017
NCT03605719 Not yet recruiting Recurrent Plasma Cell Myeloma Emory University July 30, 2018
NCT03063450 Recruiting Mesothelioma University of Southampton February 24, 2017
NCT02904226 Recruiting Cancer Jounce Therapeutics, Inc. September 16, 2016
NCT02656706 Recruiting Melanoma Maria Constantinou January 15, 2016
NCT03520634 Recruiting Melanoma University Medical Center Groningen May 10, 2018
NCT03340129 Not yet recruiting Melanoma Stage Iv Melanoma Institute Australia November 13, 2017
NCT03475134 Recruiting Metastatic Melanoma Centre Hospitalier Universitaire Vaudois March 23, 2018
NCT03371992 Enrolling by invitation Non Small Cell Lung Cancer Nilogen Oncosystems December 13, 2017
NCT02754726 Recruiting Untreated Metastatic Pancreatic Ductal Adenocarcinoma HonorHealth Research Institute April 28, 2016
NCT03544723 Recruiting Recurrent Head and Neck Cancer MultiVir, Inc. June 4, 2018
NCT01928576 Recruiting Non-Small Lung Cancer, Epigenetic Therapy Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins August 26, 2013
NCT03469960 Recruiting Non-Small Cell Lung Cancer Metastatic Intergroupe Francophone de Cancerologie Thoracique March 19, 2018
NCT02631447 Recruiting Metastatic Melanoma Fondazione Melanoma Onlus December 16, 2015
NCT02419417 Recruiting Advanced Tumors Bristol-Myers Squibb April 17, 2015
NCT03459222 Recruiting Advanced Cancer Bristol-Myers Squibb March 8, 2018
NCT01968109 Recruiting Neoplasms by Site Bristol-Myers Squibb October 23, 2013
NCT02061761 Recruiting Hematologic Neoplasms Bristol-Myers Squibb February 13, 2014
NCT03117049 Recruiting Non-Small Cell Lung Cancer Ono Pharmaceutical Co. Ltd April 17, 2017
NCT02840994 Recruiting Non-small Cell Lung Cancer (NSCLC) Bavarian Nordic, Inc. July 21, 2016
NCT03080974 Recruiting Pancreatic Adenocarcinoma University of Louisville March 15, 2017
NCT03487666 Recruiting Triple Negative Breast Cancer Georgetown University April 4, 2018
NCT03425292 Recruiting Newly Diagnosed Glioblastoma John Wayne Cancer Institute February 7, 2018
NCT03317327 Recruiting Head and Neck Squamous Cell Carcinoma Oslo University Hospital October 23, 2017
NCT03529890 Not yet recruiting Urinary Bladder Cancer Technische Universität München May 18, 2018
NCT03158129 Recruiting Non-Small Cell Lung Cancer M.D. Anderson Cancer Center May 17, 2017
NCT03307616 Recruiting Systemic Connective Tissue Disorders M.D. Anderson Cancer Center October 12, 2017
NCT02419495 Recruiting Advanced Cancers M.D. Anderson Cancer Center April 17, 2015
NCT02922283 Recruiting Melanoma University Medical Center Groningen October 4, 2016
NCT03354962 Not yet recruiting Melanoma Institut Claudius Regaud November 28, 2017
NCT03293784 Recruiting Melanoma Institut Claudius Regaud September 26, 2017
NCT03388190 Recruiting Colorectal Neoplasms Malignant University Hospital, Akershus January 2, 2018
NCT02955251 Recruiting Advanced Solid Tumors Cancer AbbVie November 4, 2016
NCT03563729 Recruiting Malignant Melanoma Inge Marie Svane June 20, 2018
NCT03647839 Not yet recruiting Colorectal Cancer Metastatic Australasian Gastro-Intestinal Trials Group August 27, 2018
NCT03387761 Recruiting Urothelial Carcinoma The Netherlands Cancer Institute January 2, 2018
NCT02848443 Recruiting Metastatic Colorectal Cancer Institut de Recherches Internationales Servier July 28, 2016
NCT02439450 Recruiting Non-small Cell Lung Cancer Heat Biologics May 8, 2015
NCT03083691 Enrolling by invitation Carcinoma, Non-Small-Cell Lung; Small Cell Lung Cancer Lung Cancer Group Cologne March 20, 2017
NCT03325816 Recruiting Small Cell Lung Cancer; Hodgkin Lymphoma Giuseppe Giaccone October 30, 2017
NCT03580408 Recruiting Hodgkin Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma The Lymphoma Academic Research Organisation July 9, 2018
NCT03305445 Recruiting Relapsed Diffuse Large B-Cell Lymphoma; Renal Medullary Carcinoma Icahn School of Medicine at Mount Sinai October 10, 2017
NCT03274258 Recruiting Renal Medullary Carcinoma; Prostate Cancer M.D. Anderson Cancer Center September 6, 2017
NCT03689699 Not yet recruiting Prostate Cancer; Carcinoma, Renal Cell Charles G. Drake September 28, 2018
NCT02917772 Recruiting Carcinoma, Renal Cell; Cervical Cancer AIO-Studien-gGmbH September 28, 2016
NCT03298893 Recruiting Cervical Cancer; Leukemia Institut Curie October 2, 2017
NCT02530463 Recruiting Leukemia; Leukemia M.D. Anderson Cancer Center August 21, 2015
NCT02420912 Recruiting Leukemia; Leukemia M.D. Anderson Cancer Center April 20, 2015
NCT02532231 Recruiting Leukemia; Kidney Cancer M.D. Anderson Cancer Center August 25, 2015
NCT03433534 Recruiting Kidney Cancer; Stage IIIC Skin Melanoma University Hospital, Tours February 14, 2018
NCT02941744 Recruiting Stage IIIC Skin Melanoma; Bladder Cancer Universitair Ziekenhuis Brussel October 21, 2016
NCT02553642 Recruiting Bladder Cancer; Melanoma Memorial Sloan Kettering Cancer Center September 17, 2015
NCT01585194 Active, not recruiting Melanoma; Malignant Neoplasms of Respiratory and Intrathoracic Organs M.D. Anderson Cancer Center April 25, 2012
NCT03391869 Recruiting Malignant Neoplasms of Respiratory and Intrathoracic Organs; Small Cell Lung Cancer M.D. Anderson Cancer Center January 5, 2018
NCT03043599 Active, not recruiting Small Cell Lung Cancer; Microsatellite Stable (MSS) Colorectal Adenocarcinomas H. Lee Moffitt Cancer Center and Research Institute February 6, 2017
NCT03642067 Not yet recruiting Microsatellite Stable (MSS) Colorectal Adenocarcinomas; Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins August 22, 2018
NCT03607890 Not yet recruiting Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy; Acute Myeloid Leukemia Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 31, 2018
NCT03417154 Recruiting Acute Myeloid Leukemia; Merkel Cell Carcinoma Masonic Cancer Center, University of Minnesota January 31, 2018
NCT03071406 Recruiting Merkel Cell Carcinoma; Malignant Neoplasms of Digestive Organs H. Lee Moffitt Cancer Center and Research Institute March 6, 2017
NCT03222076 Recruiting Malignant Neoplasms of Digestive Organs; Acral Lentiginous Melanoma M.D. Anderson Cancer Center July 19, 2017
NCT02978443 Recruiting Acral Lentiginous Melanoma; Recurrent Non-Small Cell Lung Carcinoma Georgetown University December 1, 2016
NCT03121417 Recruiting Recurrent Non-Small Cell Lung Carcinoma; Neuroendocrine Tumors Emory University April 20, 2017
NCT03420521 Recruiting Neuroendocrine Tumors; Immunotherapy Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins February 2, 2018
NCT03003637 Recruiting Immunotherapy; Refractory or Recurrent Hypermutated Malignancies The Netherlands Cancer Institute December 28, 2016
NCT02992964 Recruiting Refractory or Recurrent Hypermutated Malignancies; Breast Neoplasms The Hospital for Sick Children December 14, 2016
NCT02309177 Active, not recruiting Breast Neoplasms; Prostate Cancer Celgene December 5, 2014
NCT03543189 Recruiting Prostate Cancer; Larynx H. Lee Moffitt Cancer Center and Research Institute June 1, 2018
NCT03162731 Recruiting Larynx; Prostate Cancer Sidney Kimmel Cancer Center at Thomas Jefferson University May 22, 2017
NCT03572478 Recruiting Prostate Cancer; Biliary Tract Cancer University of Chicago June 28, 2018
NCT02829918 Recruiting Biliary Tract Cancer; Recurrent Plasma Cell Myeloma H. Lee Moffitt Cancer Center and Research Institute July 12, 2016
NCT03333746 Recruiting Recurrent Plasma Cell Myeloma; MGMT-unmethylated Glioblastoma (GBM) Yvonne Efebera November 7, 2017
NCT03367715 Recruiting MGMT-unmethylated Glioblastoma (GBM); Childhood Solid Tumor New York University School of Medicine December 11, 2017
NCT03585465 Not yet recruiting Childhood Solid Tumor; Kidney Cancer Centre Oscar Lambret July 13, 2018
NCT03568435 Active, not recruiting Kidney Cancer; Metastatic Renal Cell Cancer Bristol-Myers Squibb June 25, 2018
NCT02899078 Recruiting Metastatic Renal Cell Cancer; Melanoma University of California, Davis September 14, 2016
NCT02847728 Recruiting Melanoma; Soft Tissue Sarcoma Bristol-Myers Squibb July 28, 2016
NCT03277924 Recruiting Soft Tissue Sarcoma; Hepatocellular Carcinoma Grupo Espanol de Investigacion en Sarcomas September 11, 2017
NCT03655613 Recruiting Hepatocellular Carcinoma; Urothelial Carcinoma CBT Pharmaceuticals (Australia) Pty Ltd August 31, 2018
NCT02845323 Recruiting Urothelial Carcinoma; Lip, Oral Cavity and Pharynx Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 27, 2016
NCT03238365 Recruiting Lip, Oral Cavity and Pharynx; Gastric Cancer Sidney Kimmel Cancer Center at Thomas Jefferson University August 3, 2017
NCT02999295 Recruiting Gastric Cancer; Uveal Melanoma National Cancer Center, Japan December 21, 2016
NCT02913417 Recruiting Uveal Melanoma; Colorectal Cancer David Minor, MD September 23, 2016
NCT03184870 Recruiting Colorectal Cancer; Carcinoma, Non-Small-Cell Lung Bristol-Myers Squibb June 14, 2017
NCT03669523 Not yet recruiting Carcinoma, Non-Small-Cell Lung; Lung Cancer Centre Hospitalier de la Région d'Annecy September 13, 2018
NCT03195491 Active, not recruiting Lung Cancer; Advanced Renal Cell Carcinoma Bristol-Myers Squibb June 22, 2017
NCT02231749 Active, not recruiting Advanced Renal Cell Carcinoma; Melanoma Bristol-Myers Squibb September 4, 2014
NCT03618641 Recruiting Melanoma; Breast Cancer Diwakar Davar August 7, 2018
NCT03409198 Recruiting Breast Cancer; Melanoma Oslo University Hospital January 24, 2018
NCT03685890 Not yet recruiting Melanoma; Solid Tumor Sahlgrenska University Hospital, Sweden September 26, 2018
NCT03707808 Recruiting Solid Tumor; Glioblastoma Universitair Ziekenhuis Brussel October 16, 2018
NCT03707457 Not yet recruiting Glioblastoma; Metastatic Solid Tumors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins October 16, 2018
NCT03388632 Recruiting Metastatic Solid Tumors; Renal Cell Carcinoma National Cancer Institute (NCI) January 3, 2018
NCT01472081 Active, not recruiting Renal Cell Carcinoma; Limited Stage Small Cell Lung Cancer Bristol-Myers Squibb November 16, 2011
NCT02046733 Recruiting Limited Stage Small Cell Lung Cancer; Gliosarcoma European Thoracic Oncology Platform January 28, 2014
NCT02311920 Active, not recruiting Gliosarcoma; Adenocarcinoma of the Stomach National Cancer Institute (NCI) December 9, 2014
NCT03647969 Not yet recruiting Adenocarcinoma of the Stomach; Hepatocellular Carcinoma IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest August 27, 2018
NCT03383458 Recruiting Hepatocellular Carcinoma; Breast Cancer Bristol-Myers Squibb December 26, 2017
NCT03523572 Recruiting Breast Cancer; Triple-Negative Breast Cancer Daiichi Sankyo, Inc. May 14, 2018
NCT02393794 Recruiting Triple-Negative Breast Cancer; Malignant Solid Tumor Priyanka Sharma March 19, 2015
NCT02518958 Active, not recruiting Malignant Solid Tumor; Melanoma EpicentRx, Inc. August 10, 2015
NCT03329846 Active, not recruiting Melanoma; Unresectable Stage III Melanoma Bristol-Myers Squibb November 6, 2017
NCT03235245 Not yet recruiting Unresectable Stage III Melanoma; Recurrent Squamous Cell Lung Carcinoma European Organisation for Research and Treatment of Cancer - EORTC August 1, 2017
NCT02785952 Recruiting Recurrent Squamous Cell Lung Carcinoma; Gastric Adenocarcinoma Southwest Oncology Group May 30, 2016
NCT02864381 Active, not recruiting Gastric Adenocarcinoma; MSS Gilead Sciences August 12, 2016
NCT03271047 Active, not recruiting MSS; Unresectable Melanoma Array BioPharma September 1, 2017
NCT01927419 Active, not recruiting Unresectable Melanoma; Lung Cancer Bristol-Myers Squibb August 22, 2013
NCT03575793 Recruiting Lung Cancer; Gastric Cancer Jyoti Malhotra July 3, 2018
NCT02872116 Recruiting Gastric Cancer; Advanced Melanoma Bristol-Myers Squibb August 19, 2016
NCT01621490 Active, not recruiting Advanced Melanoma; Advanced Solid Tumors Bristol-Myers Squibb June 18, 2012
NCT02253992 Recruiting Advanced Solid Tumors; Advanced Soft Tissue Sarcoma Bristol-Myers Squibb October 1, 2014
NCT03138161 Recruiting Advanced Soft Tissue Sarcoma; Gastroesophageal Cancer Sarcoma Oncology Research Center, LLC May 3, 2017
NCT03610711 Not yet recruiting Gastroesophageal Cancer; Advanced Solid Tumors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins August 1, 2018
NCT02261298 Active, not recruiting Advanced Solid Tumors; Thymoma Type B3 Ono Pharmaceutical Co. Ltd October 10, 2014
NCT03134118 Recruiting Thymoma Type B3; Lung Cancer European Organisation for Research and Treatment of Cancer - EORTC April 28, 2017
NCT02664181 Recruiting Lung Cancer; Head and Neck Cancer Case Comprehensive Cancer Center January 26, 2016
NCT03646461 Not yet recruiting Head and Neck Cancer; Melanoma University of California, San Diego August 24, 2018
NCT02374242 Active, not recruiting Melanoma; Colorectal Neoplasms Malignant Melanoma Institute Australia February 27, 2015
NCT03507699 Not yet recruiting Colorectal Neoplasms Malignant; Adverse Effect Sheba Medical Center April 25, 2018
NCT03316417 Not yet recruiting Adverse Effect; HPV-Related Squamous Cell Carcinoma Hospices Civils de Lyon October 20, 2017
NCT03107182 Recruiting HPV-Related Squamous Cell Carcinoma; Locally Advanced Cancer University of Chicago April 11, 2017
NCT03119428 Recruiting Locally Advanced Cancer; Metastatic Pancreatic Cancer OncoMed Pharmaceuticals, Inc. April 18, 2017
NCT02866383 Recruiting Metastatic Pancreatic Cancer; Renal Cell Carcinoma Herlev Hospital August 15, 2016
NCT03663946 Not yet recruiting Renal Cell Carcinoma; Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Bristol-Myers Squibb September 10, 2018
NCT03620123 Recruiting Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck; Melanoma AIO-Studien-gGmbH August 8, 2018
NCT02600143 Recruiting Melanoma; Melanoma University Medical Center Groningen November 9, 2015
NCT02519322 Active, not recruiting Melanoma; Malignant Neoplasms of Respiratory and Intrathoracic Organs M.D. Anderson Cancer Center August 10, 2015
NCT03110978 Recruiting Malignant Neoplasms of Respiratory and Intrathoracic Organs; Metastatic Solid Tumor Cancer M.D. Anderson Cancer Center April 12, 2017
NCT02842125 Not yet recruiting Metastatic Solid Tumor Cancer; Head and Neck Cancer MultiVir, Inc. July 22, 2016
NCT03247712 Recruiting Head and Neck Cancer; Hematologic Malignancies Providence Health & Services August 14, 2017
NCT02663518 Recruiting Hematologic Malignancies; Trillium Therapeutics Inc. January 26, 2016
NCT02933346 Active, not recruiting Non-small Cell Lung Cancer; Nivolumab; Long-term Adverse Effects Intergroupe Francophone de Cancerologie Thoracique October 14, 2016
NCT03554317 Recruiting Castration-resistant Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins June 13, 2018
NCT03597009 Not yet recruiting Malignant Pleural Effusion; Stage IV Metastatic Cancer; Lung Cancer UNC Lineberger Comprehensive Cancer Center July 24, 2018
NCT02978404 Recruiting Clear-Cell Metastatic Renal Cell Carcinoma; Non Small Cell Lung Cancer Metastatic; Brain Metastases, Adult Centre hospitalier de l'Université de Montréal (CHUM) December 1, 2016
NCT03304093 Recruiting Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage IIIB; HIV/AIDS Intergroupe Francophone de Cancerologie Thoracique October 6, 2017
NCT02498600 Active, not recruiting Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma National Cancer Institute (NCI) July 15, 2015
NCT03219775 Recruiting Transitional Cell Carcinoma; Advanced Cancer; Metastatic Cancer AIO-Studien-gGmbH July 18, 2017
NCT03245892 Recruiting High Grade Serous Ovarian; Fallopian Tube; Primary Peritoneal Cancer Memorial Sloan Kettering Cancer Center August 10, 2017
NCT03015740 Recruiting Malignant Neoplasms of Urinary Tract; Other Disorders of Kidney and Ureter; Renal Cell Carcinoma M.D. Anderson Cancer Center January 10, 2017
NCT03377023 Recruiting Non Small Cell Lung Cancer; Lung Cancer, Nonsmall Cell; Non Small Cell Lung Cancer Metastatic H. Lee Moffitt Cancer Center and Research Institute December 19, 2017
NCT02718066 Recruiting Melanoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer HUYA Bioscience International March 24, 2016
NCT03652142 Recruiting HNSCC; DNA Damage; DNA Double Strand Break Attikon Hospital August 29, 2018
NCT02464657 Recruiting Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome M.D. Anderson Cancer Center June 8, 2015
NCT03693846 Not yet recruiting Mucinous Neoplasm; Colorectal Tumor; Appendiceal Tumor Abramson Cancer Center of the University of Pennsylvania October 3, 2018
NCT03104439 Recruiting Microsatellite Stable Colorectal Cancer; Pancreatic Cancer; MSI High Colorectal Cancer Massachusetts General Hospital April 7, 2017
NCT02529072 Active, not recruiting Malignant Glioma; Astrocytoma; Glioblastoma Gary Archer Ph.D. August 19, 2015
NCT03132038 Recruiting Salivary Gland Carcinoma; Metastatic Cancer; Recurrent Cancer UNICANCER April 27, 2017
NCT03502733 Recruiting Ann Arbor Stage III Lymphoma; Ann Arbor Stage IV Lymphoma; Metastatic Malignant Solid Neoplasm National Cancer Institute (NCI) April 19, 2018
NCT03173950 Recruiting Ependymoma; Meningioma; Chordoma National Cancer Institute (NCI) June 2, 2017
NCT03316274 Recruiting Kaposi Sarcoma; HIV/AIDS; Immunosuppression University of California, San Francisco October 20, 2017
NCT03575598 Recruiting Squamous Cell Carcinoma, Head And Neck; Squamous Cell Carcinoma Mouth; Squamous Cell Carcinoma of the Oral Cavity University Health Network, Toronto July 2, 2018
NCT03421652 Recruiting Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7 Barbara Ann Karmanos Cancer Institute February 5, 2018
NCT02873962 Active, not recruiting Peritoneal Cancer; Ovarian Cancer; Fallopian Tube Cancer Dana-Farber Cancer Institute August 22, 2016
NCT03604978 Not yet recruiting Grade II Meningioma; Grade III Meningioma; Recurrent Meningioma National Cancer Institute (NCI) July 30, 2018
NCT03600155 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia M.D. Anderson Cancer Center July 25, 2018
NCT02314169 Recruiting Anal Canal Squamous Cell Carcinoma; Metastatic Anal Canal Carcinoma; Stage IV Anal Canal Cancer AJCC v6 and v7 National Cancer Institute (NCI) December 11, 2014
NCT03044613 Recruiting Gastric Cancer; Esophageal Cancer; GastroEsophageal Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins February 7, 2017
NCT02716948 Recruiting Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Spine; Stage IV Skin Melanoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins March 23, 2016
NCT03342417 Recruiting Breast Cancer Female; Ovarian Cancer; Gastric Cancer ExcellaBio LLC November 17, 2017
NCT03569436 Recruiting Cancer of Head and Neck; Cancer of the Head; Cancer of the Neck Bristol-Myers Squibb June 26, 2018
NCT03406715 Recruiting Small Cell Lung Cancer; Lung Cancer; Relapsed Small Cell Lung Cancer H. Lee Moffitt Cancer Center and Research Institute January 23, 2018
NCT03583086 Recruiting Thymic Carcinoma; Non-small Cell Lung Cancer; Refractory Thoracic Tumors Vanderbilt-Ingram Cancer Center July 11, 2018
NCT03065179 Recruiting Kidney Cancer Metastatic; Kidney Cancer; Kidney Cancer, Stage IV University of Texas Southwestern Medical Center February 27, 2017
NCT03465592 Recruiting Sarcoma; Solid Tumor, Adult; Solid Tumor, Childhood Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins March 14, 2018
NCT02923934 Recruiting Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm Olivia Newton-John Cancer Research Institute October 5, 2016
NCT02775292 Recruiting Adult Solid Neoplasm; Childhood Solid Neoplasm; Metastatic Neoplasm Jonsson Comprehensive Cancer Center May 17, 2016
NCT03572582 Recruiting Carcinoma, Hepatocellular; Hepatic Carcinoma; Hepatocellular Cancer AIO-Studien-gGmbH June 28, 2018
NCT03502330 Recruiting Advanced Melanoma; Non-small Cell Lung Cancer; Renal Cell Carcinoma Yale University April 18, 2018
NCT03061955 Active, not recruiting Influenza Virus Vaccine Adverse Reaction (Disorder); Influenza; Malignancy Advocate Health Care February 23, 2017
NCT02771626 Recruiting Clear Cell Renal Cell Carcinoma; Melanoma; Non-small Cell Lung Cancer Calithera Biosciences, Inc May 13, 2016
NCT03519256 Recruiting Bladder Cancer; Bladder Tumors; Neoplasms, Bladder Bristol-Myers Squibb May 8, 2018
NCT01592370 Recruiting Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma Bristol-Myers Squibb May 7, 2012
NCT02658890 Recruiting Advanced Cancer; Melanoma; Non-Small Cell Lung Cancer Bristol-Myers Squibb January 20, 2016
NCT02118337 Active, not recruiting Select Advanced Malignancies; Kidney Cancer; Clear Cell Renal Cell Carcinoma MedImmune LLC April 21, 2014
NCT02423343 Recruiting Solid Tumor; Non-Small Cell Lung Cancer Recurrent; Hepatocellular Carcinoma Recurrent Eli Lilly and Company April 22, 2015
NCT02831933 Recruiting Lung Squamous Cell Carcinoma Stage IV; Nonsquamous Nonsmall Cell Neoplasm of Lung; Metastatic Uveal Melanoma Eric Bernicker, MD July 13, 2016
NCT02210117 Active, not recruiting Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Cancer; Stage IV Renal Cell Cancer AJCC v7 M.D. Anderson Cancer Center August 6, 2014
NCT02658981 Recruiting Glioblastoma; Gliosarcoma; Recurrent Brain Neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins January 20, 2016
NCT02601014 Recruiting Prostate Cancer; Recurrent Prostate Carcinoma; Stage IV Prostate Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins November 10, 2015
NCT03161756 Recruiting Melanoma Stage Iv; Melanoma Stage Iii; Melanoma Australia and New Zealand Melanoma Trials Group May 22, 2017
NCT03662659 Recruiting Gastric Cancer; Cancer of the Stomach; Esophagogastric Junction Bristol-Myers Squibb September 7, 2018
NCT03661320 Not yet recruiting Bladder Cancer; Muscle-Invasive Bladder Cancer; BMS-986205 Bristol-Myers Squibb September 7, 2018
NCT02852083 Recruiting Squamous Cell Lung Cancer; Non-Squamous Cell Lung Cancer; Non-Small Cell Lung Cancer University Hospital Regensburg August 2, 2016
NCT03638375 Recruiting Toxicity, Drug; Adverse Drug Event; Effects of Immunotherapy Leiden University Medical Center August 20, 2018
NCT03650894 Not yet recruiting Breast Neoplasm Female Providence Health & Services August 29, 2018
NCT03041181 Recruiting Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Nasser Hanna, M.D. February 2, 2017
NCT02737787 Active, not recruiting Ovarian Cancer Memorial Sloan Kettering Cancer Center April 14, 2016
NCT02720484 Active, not recruiting Metastatic Carcinoma in the Adrenal Cortex Northwestern University March 28, 2016
NCT02595918 Recruiting Clear Cell Renal Cell Carcinoma National Cancer Institute (NCI) November 4, 2015
NCT02967133 Active, not recruiting Non-Small-Cell Lung Cancer Metastatic Alliance Foundation Trials, LLC. November 18, 2016
NCT03623854 Not yet recruiting Chordoma Jonsson Comprehensive Cancer Center August 9, 2018
NCT03575234 Not yet recruiting Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma Emory University July 2, 2018
NCT03258567 Recruiting Epstein-Barr Virus Infections National Cancer Institute (NCI) August 23, 2017
NCT03628209 Not yet recruiting Osteosarcoma H. Lee Moffitt Cancer Center and Research Institute August 14, 2018
NCT03055013 Recruiting Sarcomatoid Renal Cell Carcinoma National Cancer Institute (NCI) February 16, 2017
NCT03652233 Not yet recruiting Recurrent Squamous Cell Carcinoma of the Head or Neck Vanderbilt-Ingram Cancer Center August 29, 2018
NCT03662074 Not yet recruiting Small Cell Lung Carcinoma Wake Forest University Health Sciences September 7, 2018
NCT03057795 Recruiting Classical Hodgkin Lymphoma City of Hope Medical Center February 20, 2017
NCT03016871 Recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present City of Hope Medical Center January 11, 2017
NCT02892734 Recruiting HER2/Neu Negative Northwestern University September 8, 2016
NCT02834247 Recruiting Triple-Negative Breast Neoplasms Millennium Pharmaceuticals, Inc. July 15, 2016
NCT03484819 Not yet recruiting Recurrent Diffuse Large B-Cell Lymphoma National Cancer Institute (NCI) April 2, 2018
NCT03377361 Recruiting Colorectal Cancer Bristol-Myers Squibb December 19, 2017
NCT03558750 Recruiting Recurrent Central Nervous System Lymphoma Vanderbilt-Ingram Cancer Center June 15, 2018
NCT03251924 Recruiting Cancer Bristol-Myers Squibb August 16, 2017
NCT02060188 Active, not recruiting Microsatellite Unstable Colorectal Cancer Bristol-Myers Squibb February 11, 2014
NCT00730639 Active, not recruiting Metastatic Castration-resistant Prostrate Cancer Bristol-Myers Squibb August 8, 2008
NCT03347838 Not yet recruiting Bronchial Dysplasia University of Colorado, Denver November 20, 2017
NCT03092674 Recruiting Acute Myeloid Leukemia National Cancer Institute (NCI) March 28, 2017
NCT03704077 Not yet recruiting Gastric Cancer Bristol-Myers Squibb October 12, 2018
NCT03044626 Recruiting Carcinoma, Non-Small-Cell Lung; Metastatic Lung Cancer; Nonsmall Cell Lung Cancer; Lung Adenocarcinoma Metastatic; Large Cell Lung Carcinoma Metastatic AIO-Studien-gGmbH February 7, 2017
NCT02335918 Active,  not recruiting Squamous Cell Carcinoma of the Head and Neck (SCCHN); Ovarian Carcinoma-Enrollment Completed; Colorectal Cancer (CRC)-Enrollment Completed; Renal Cell Carcinoma (RCC) (Phase ll Only); Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed Celldex Therapeutics January 12, 2015
NCT03123783 Recruiting Cancer; Non Small Cell Lung Cancer Metastatic; Metastatic Melanoma; Neoplasm of Lung; Melanoma Apexigen, Inc. April 21, 2017
NCT03606174 Recruiting Urothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Ureter; Urothelial Carcinoma of the Renal Pelvis and Ureter; Urothelial Carcinoma Urethra Mirati Therapeutics Inc. July 30, 2018
NCT02705105 Active,  not recruiting Solid Tumor; Cancer; Carcinoma; Hepatocellular Carcinoma; HCC Kyowa Kirin Pharmaceutical Development, Inc. March 10, 2016
NCT03620578 Recruiting Non Hodgkin Lymphoma; Lymphoma,  B-Cell; High-grade B-cell Lymphoma; MYC Translocation; BCL-2 Translocation Stichting Hemato-Oncologie voor Volwassenen Nederland August 8, 2018
NCT03588936 Recruiting Multiple Myeloma; Acute Leukemia; Chronic Leukemia; Lymphoma; Myelodysplastic Syndromes Medical College of Wisconsin July 17, 2018
NCT03012581 Recruiting Carcinoma,  Renal Cell; Head and Neck Neoplasm; Skin Neoplasms; Microsatellite Instability; Penile Neoplasms UNICANCER January 6, 2017
NCT02837029 Recruiting Stage IIIA Hepatocellular Carcinoma; Stage IIIB Hepatocellular Carcinoma; Stage IIIC Hepatocellular Carcinoma; Stage IVA Hepatocellular Carcinoma; Stage IVB Hepatocellular Carcinoma Northwestern University July 19, 2016
NCT03190174 Recruiting Undifferentiated Pleomorphic Sarcoma; Liposarcoma; Chondrosarcoma; Osteosarcoma; Ewing Sarcoma Sarcoma Oncology Research Center, LLC June 16, 2017
NCT02595944 Recruiting Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) November 4, 2015
NCT02947386 Recruiting EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer Roswell Park Cancer Institute October 27, 2016
NCT02819804 Active,  not recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic Leukemia; Refractory Childhood Acute Lymphoblastic Leukemia Northwestern University June 30, 2016
NCT03048500 Recruiting Recurrent Non-Small Cell Lung Carcinoma; Stage III Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer Northwestern University February 9, 2017
NCT02955290 Recruiting ALK Gene Mutation; EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer Roswell Park Cancer Institute November 4, 2016
NCT03655002 Not yet recruiting Recurrent Hepatocellular Carcinoma; Refractory Liver Carcinoma; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8 City of Hope Medical Center August 31, 2018
NCT03355976 Recruiting Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Extra Renal Origin; Clear Cell Adenocarcinoma Don Dizon November 29, 2017
NCT03033576 Recruiting Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7 National Cancer Institute (NCI) January 27, 2017
NCT03014804 Not yet recruiting Giant Cell Glioblastoma; Gliosarcoma; Oligodendroglioma; Recurrent Glioblastoma; Small Cell Glioblastoma Jonsson Comprehensive Cancer Center January 9, 2017
NCT01703949 Recruiting CD30-Positive Neoplastic Cells Present; Recurrent Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma University of Washington October 11, 2012
NCT02983045 Recruiting Melanoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Triple Negative Breast Cancer Nektar Therapeutics December 6, 2016
NCT03631641 Recruiting Colon Adenoma; Colon Carcinoma; Lynch Syndrome; MLH1 Gene Mutation; MSH2 Gene Mutation Joanne Jeter August 15, 2018
NCT03215810 Recruiting Non-Small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer; Squamous Cell Carcinoma; Advanced NSCLC; Adenosquamous Carcinoma; Adenocarcinomas H. Lee Moffitt Cancer Center and Research Institute July 12, 2017
NCT02823990 Active, not recruiting Recurrent Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer Karen Kelly July 6, 2016
NCT02257528 Active, not recruiting Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Recurrent Cervical Carcinoma; Stage IV Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVB Cervical Cancer AJCC v6 and v7 National Cancer Institute (NCI) October 6, 2014
NCT02846792 Recruiting ALK Gene Translocation; EGFR Activating Mutation; Recurrent Non-Small Cell Lung Carcinoma; ROS1 Gene Translocation; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7 University of Washington July 27, 2016
NCT03455452 Recruiting Renal Cell Carcinoma; Renal Cell Cancer; Adenocarcinoma Of Kidney; Adenocarcinoma, Renal Cell; Kidney Cancer; Cancer of the Kidney Bristol-Myers Squibb March 6, 2018
NCT03061188 Recruiting Advanced Solid Neoplasm; Aggressive Non-Hodgkin Lymphoma; Recurrent Solid Neoplasm; Refractory Mantle Cell Lymphoma; T-Cell Non-Hodgkin Lymphoma; Unresectable Solid Neoplasm Northwestern University February 23, 2017
NCT03595124 Not yet recruiting Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; TFE3 Gene Translocation; TFEB Gene Translocation National Cancer Institute (NCI) July 23, 2018
NCT02526017 Active, not recruiting Advanced Solid Tumors, Including But Not Limited to Lung Cancer; Head and Neck Cancer; Pancreatic Cancer; Ovarian Cancer; Renal Cell Carcinoma; Malignant Glioma Five Prime Therapeutics, Inc. August 18, 2015
NCT03409848 Recruiting Gastric Cancer; Esophageal Cancer; Adenocarcinoma Gastric; HER2 Positive Gastric Cancer; Metastatic Gastric Cancer; GastroEsophageal Cancer AIO-Studien-gGmbH January 24, 2018
NCT03358719 Recruiting Acute Myeloid Leukemia; Blasts 30 Percent or Less of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Refractory Anemia Roswell Park Cancer Institute December 2, 2017
NCT03177239 Recruiting Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Xp11 Translocation Carcinoma Australian and New Zealand Urogenital and Prostate Cancer Trials Group June 6, 2017
NCT03233347 Recruiting Ann Arbor Stage I Hodgkin Lymphoma; Ann Arbor Stage IA Hodgkin Lymphoma; Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma Academic and Community Cancer Research United July 28, 2017
NCT03425461 Recruiting Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7 Jonsson Comprehensive Cancer Center February 7, 2018
NCT03311334 Recruiting Neoplasms; Melanoma; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Urothelial Neoplasm Boston Biomedical, Inc October 17, 2017
NCT03241745 Recruiting Uterine Cancer; Endometrial Carcinoma; Carcinosarcoma; Leiomyosarcoma; Undifferentiated Sarcoma; High Grade Endometrial Stromal Sarcoma; Clear Cell Carcinoma Memorial Sloan Kettering Cancer Center August 7, 2017
NCT02973113 Recruiting NonHodgkin Lymphoma; Lymphoproliferative Disorders; EBV Related Lymphoma; EBV-Related PTLD; Hodgkin Lymphoma; EBV Related Non-Hodgkin's Lymphoma; EBV Related Hodgkin's Lymphoma Baylor College of Medicine November 25, 2016
NCT03444766 Recruiting Non-Small Cell Lung Cancer (NSCLC); Non-Small-Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms Bristol-Myers Squibb February 23, 2018
NCT03333616 Recruiting Genitourinary Cancer; Adrenocortical Carcinoma; Non-urothelial Bladder; Non-urothelial Upper Tract; Penile Cancer; Non-adenocarcinoma Prostate Cancer; Refractory Germ-cell Dana-Farber Cancer Institute November 7, 2017
NCT03522246 Recruiting Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Newly Diagnosed; FIGO Stage III-IV; Partial Response; Complete Response Clovis Oncology, Inc. May 11, 2018
NCT02339558 Active, not recruiting Nasopharyngeal Nonkeratinizing Carcinoma; Recurrent Nasopharynx Carcinoma; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage IV Nasopharyngeal Carcinoma AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVC Nasopharyngeal Carcinoma AJCC v7 National Cancer Institute (NCI) January 15, 2015
NCT03146650 Recruiting Major Salivary Gland Carcinoma; Minor Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVC Major Salivary Gland Carcinoma Northwestern University May 10, 2017
NCT03025256 Recruiting Acral Lentiginous Melanoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Leptomeningeal Neoplasm; Metastatic Melanoma; Metastatic Uveal Melanoma; Mucosal Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8 M.D. Anderson Cancer Center January 19, 2017
NCT03439891 Recruiting Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8 University of California, San Francisco February 20, 2018
NCT02879695 Recruiting B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; CD19-Positive Neoplastic Cells Present; Mixed Phenotype Acute Leukemia; Mixed Phenotype Acute Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia National Cancer Institute (NCI) August 26, 2016
NCT03050060 Recruiting Metastatic Renal Cell Cancer; Recurrent Melanoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Renal Cell Carcinoma; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IV Non-Small Cell Lung Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7 University of Washington February 10, 2017
NCT02982486 Not yet recruiting Soft Tissue Sarcoma; Bone Sarcoma; Chondrosarcoma; Gastrointestinal Stromal Sarcoma; Ewing's Tumor Metastatic; Ewing's Tumor Recurrent; Osteosarcoma; Desmoplastic Small Round Cell Tumor Assaf-Harofeh Medical Center December 5, 2016
NCT03435640 Recruiting Melanoma; Merkel Cell Carcinoma; Triple Negative Breast Cancer; Ovarian Cancer; Renal Cell Carcinoma; Colorectal Cancer; Urothelial Carcinoma; Sarcoma Nektar Therapeutics February 16, 2018
NCT03366766 Recruiting Non-Squamous Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer Sidney Kimmel Cancer Center at Thomas Jefferson University December 8, 2017
NCT03233711 Recruiting Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage II Anal Canal Cancer AJCC v6 and v7; Stage IIB Anal Cancer AJCC v8; Stage III Anal Canal Cancer AJCC v6 and v7; Stage IIIA Anal Canal Cancer AJCC v6 and v7; Stage IIIB Anal Canal Cancer AJCC v6 and v7 National Cancer Institute (NCI) July 31, 2017
NCT03704714 Not yet recruiting Aggressive Non-Hodgkin Lymphoma; B-Cell Non-Hodgkin Lymphoma; CD20 Positive; Diffuse Large B-Cell Lymphoma Unclassifiable; Intravascular Large B-Cell Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Northwestern University October 15, 2018
NCT03576963 Not yet recruiting Colorectal Adenocarcinoma; CpG Island Methylator Phenotype; Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 University of Southern California July 4, 2018
NCT03695250 Not yet recruiting Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma Edward Kim October 4, 2018
NCT03370276 Recruiting Squamous Cell Carcinoma of the Oropharynx; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Oral Cavity; Squamous Cell Carcinoma of the Hypopharynx; Squamous Cell Carcinoma of the Paranasal Sinus; Head and Neck Squamous Cell Carcinoma; Squamous Cell Cancer; Head and Neck Carcinoma H. Lee Moffitt Cancer Center and Research Institute December 12, 2017
NCT02897765 Active, not recruiting Urinary Bladder Cancer; Bladder Tumors; Transitional Cell Carcinoma of the Bladder; Malignant Melanoma; Melanoma; Skin Cancer; Carcinoma, Non-Small-Cell Lung; Lung Cancer Neon Therapeutics, Inc. September 13, 2016
NCT03416244 Recruiting Esophageal Cancer; Oesophageal Cancer; Oesophageal Cancer Metastatic; Esophageal Cancer Metastatic; Esophageal Cancers NOS; Oesophageal Cancer Nos; GastroEsophageal Cancer; Gastrooesophageal Cancer AIO-Studien-gGmbH January 31, 2018
NCT02327078 Active, not recruiting B-cell Malignancies; Colorectal Cancer (CRC); Head and Neck Cancer; Lung Cancer; Lymphoma; Melanoma; Ovarian Cancer; Glioblastoma Incyte Corporation December 30, 2014
NCT02224781 Recruiting BRAF NP_004324.2:p.V600X; Metastatic Melanoma; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7 National Cancer Institute (NCI) August 25, 2014
NCT01940809 Active, not recruiting BRAF V600E Mutation Present; BRAF V600K Mutation Present; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7 National Cancer Institute (NCI) September 12, 2013
NCT02637531 Recruiting Advanced Solid Tumors (Part A/B/C/D); Non-small Cell Lung Cancer (Part E); Melanoma (Part E); Squamous Cell Cancer of the Head and Neck (Part E); Triple Negative Breast Cancer (Part F); Adrenocortical Carcinoma (Part G); Mesothelioma (Part G); High-circulating Myeloid-derived Suppressor Cells (Part H) Infinity Pharmaceuticals, Inc. December 22, 2015
NCT02408861 Recruiting Advanced Malignant Solid Neoplasm; Anal Carcinoma; HIV Infection; Kaposi Sarcoma; Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma; Unresectable Solid Neoplasm National Cancer Institute (NCI) April 6, 2015
NCT02397720 Recruiting Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia M.D. Anderson Cancer Center March 25, 2015
NCT03518320 Recruiting Bladder Cancer TNM Staging Primary Tumor (T) T2; Bladder Cancer TNM Staging Primary Tumor (T) T2A; Bladder Cancer TNM Staging Primary Tumor (T) T2B; Bladder Cancer TNM Staging Primary Tumor (T) T3; Bladder Cancer TNM Staging Primary Tumor (T) T3A; Bladder Cancer TNM Staging Primary Tumor (T) T3B; Bladder Cancer TNM Staging Regional Lymph Node (N) N0; Bladder Cancer TNM Staging Regional Lymph Node (N) N1; Bladder Cancer TNM Staging Distant Metastasis (M) M0 Taris Biomedical LLC May 8, 2018
NCT03667716 Recruiting Advanced Cancer; Ovarian Cancer; Breast Cancer; Lung Cancer; Endometrial Cancer; Ovarian Neoplasm; Triple Negative Breast Cancer; Lung Neoplasm; Neoplasm Malignant Compugen Ltd September 12, 2018
NCT03656627 Not yet recruiting Autoimmune Diseases; Non-small Cell Lung Cancer; Rheumatoid Arthritis; Psoriasis; Giant Cell Arteritis; Polymyalgia Rheumatica; Systemic Lupus Erythematosus; Crohn Disease; Multiple Sclerosis; Ulcerative Colitis Alliance Foundation Trials, LLC. September 3, 2018
NCT02631746 Active, not recruiting Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; CD3 Positive; CD4-Positive Neoplastic Cells Present; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection; Hypercalcemia; Lymphomatous Adult T-Cell Leukemia/Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma; Smoldering Adult T-Cell Leukemia/Lymphoma National Cancer Institute (NCI) December 16, 2015
NCT03367741 Recruiting Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IIIC1 Uterine Corpus Cancer AJCC v7; Stage IIIC2 Uterine Corpus Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 National Cancer Institute (NCI) December 11, 2017
NCT02453620 Recruiting Breast Adenocarcinoma; HER2/Neu Negative; Invasive Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Unresectable Solid Neoplasm National Cancer Institute (NCI) May 25, 2015
NCT02758717 Recruiting Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma Academic and Community Cancer Research United May 2, 2016
NCT01822509 Recruiting Hematopoietic Cell Transplantation Recipient; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma National Cancer Institute (NCI) April 2, 2013
NCT03373188 Recruiting Colon Carcinoma Metastatic in the Liver; Colorectal Adenocarcinoma; Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Colorectal Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer Emory University December 14, 2017
NCT03015896 Recruiting Grade 3a Follicular Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma Kami Maddocks January 10, 2017
NCT03075553 Recruiting Blastic Plasmacytoid Dendritic Cell Neoplasm; Hepatosplenic T-Cell Lymphoma; HTLV-1 Infection; NK-Cell Lymphoma, Unclassifiable; Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative; Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Mycosis Fungoides; Refractory Adult T-Cell Leukemia/Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Mycosis Fungoides; Refractory Nasal Type Extranodal NK/T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified Mayo Clinic March 9, 2017
NCT03342911 Recruiting Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma; Stage II Oropharyngeal Squamous Cell Carcinoma; Stage III Hypopharyngeal Squamous Cell Carcinoma; Stage III Laryngeal Squamous Cell Carcinoma; Stage III Oral Cavity Squamous Cell Carcinoma; Stage III Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Laryngeal Squamous Cell Carcinoma; Stage IV Oral Cavity Squamous Cell Carcinoma; Stage IV Oropharyngeal Squamous Cell Carcinoma; Stage IVA Hypopharyngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Oral Cavity Squamous Cell Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Hypopharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Oral Cavity Squamous Cell Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Hypopharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Oral Cavity Squamous Cell Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinom Sidney Kimmel Cancer Center at Thomas Jefferson University November 17, 2017
NCT02304458 Recruiting Metastatic Melanoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdomyosarcoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7 National Cancer Institute (NCI) December 2, 2014
NCT03508570 Recruiting Malignant Peritoneal Neoplasm; Malignant Retroperitoneal Neoplasm; Peritoneal Carcinomatosis; Recurrent Cervical Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IV Cervical Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8 M.D. Anderson Cancer Center April 25, 2018
NCT03604991 Not yet recruiting Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 National Cancer Institute (NCI) July 30, 2018
NCT03038672 Recruiting ALK-Positive Large B-Cell Lymphoma; Atypical Burkitt/Burkitt-Like Lymphoma; Burkitt-Like Lymphoma With 11q Aberration; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Mucocutaneous Ulcer; High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Human Herpesvirus 8-Positive Neoplastic Cells Present; Intravascular Large B-Cell Lymphoma; Large B-Cell Lymphoma With IRF4 Rearrangement; Plasmablastic Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System; Primary Effusion Lymphoma; Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Lymphomatoid Granulomatosis; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma National Cancer Institute (NCI) February 1, 2017
NCT03229278 Recruiting Lymphoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Cancer; Recurrent Bladder Carcinoma; Recurrent Classical Hodgkin Lymphoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Renal Cell Carcinoma; Stage III Bladder Cancer; Stage III Lymphoma; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage III Renal Cell Cancer; Stage III Skin Melanoma; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Skin Melanoma; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Bladder Cancer; Stage IV Lymphoma; Stage IV Non-Small Cell Lung Cancer AJCC v7; Stage IV Renal Cell Cancer; Stage IV Skin Melanoma; Stage IVA Bladder Cancer; Stage IVB Bladder Cancer; Unresectable Head and Neck Squamous Cell Carcinoma; Unresectable Solid Neoplasm Rutgers, The State University of New Jersey July 25, 2017
NCT02496208 Recruiting Bladder Small Cell Neuroendocrine Carcinoma; Clear Cell Renal Cell Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Penile Carcinoma; Metastatic Renal Cell Carcinoma; Renal Pelvis Urothelial Carcinoma; Sarcomatoid Renal Cell Carcinoma; Squamous Cell Carcinoma of the Penis; Stage III Bladder Adenocarcinoma AJCC v6 and v7; Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Penile Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Stage III Renal Pelvis Cancer AJCC v7; Stage III Ureter Cancer AJCC v7; Stage III Urethral Cancer AJCC v7; Stage IIIa Penile Cancer AJCC v7; Stage IIIb Penile Cancer AJCC v7; Stage IV Bladder Adenocarcinoma AJCC v7; Stage IV Bladder Squamous Cell Carcinoma AJCC v7; Stage IV Bladder Urothelial Carcinoma AJCC v7; Stage IV Penile Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Stage IV Renal Pelvis Cancer AJCC v7; Stage IV Ureter Cancer AJCC v7; Stage IV Urethral Cancer AJCC v7; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma National Cancer Institute (NCI) July 14, 2015
NCT02978625 Recruiting Adenoid Cystic Carcinoma; Adnexal Carcinoma; Apocrine Carcinoma; Eccrine Porocarcinoma; Extraocular Cutaneous Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Non-Melanomatous Lesion; Paget Disease; Papillary Adenocarcinoma; Primary Cutaneous Mucinous Carcinoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Spiradenocarcinoma; Squamous Cell Carcinoma of Unknown Primary Origin; Stage III Skin Cancer; Stage IV Skin Cancer; Sweat Gland Carcinoma; Trichilemmocarcinoma; Vulvar Squamous Cell Carcinoma National Cancer Institute (NCI) December 1, 2016
NCT02834013 Recruiting Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary Origin; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Placental-Site Gestational Trophoblastic Tumor; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Malignant Transformation; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma National Cancer Institute (NCI) July 15, 2016

Table 2. Approved Drugs of Nivolumab**

INN (trade name) Therapeutic area Dose Strength Route Company Marketing start Market
Opdivo Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Concentrate for solution 10 mg / mL Intravenous infusion Bristol-Myers Squibb December 22, 2014 Nivolumab Overview
Opdivo Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Concentrate for solution 10 mg / mL Intravenous infusion Bristol-Myers Squibb Pharma EEIG June 19, 2015 Nivolumab Overview
Opdivo Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Concentrate for solution 10 mg / mL Intravenous infusion Bristol-Myers Squibb Canada October 23, 2015 Nivolumab Overview
Opdivo Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Concentrate for solution 10 mg / mL Intravenous infusion Bristol-Myers Squibb Australia Pty Ltd January 16, 2016 Nivolumab Overview
Opdivo Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Concentrate for solution 10 mg / mL Intravenous infusion Ono Pharmaceutical Co., Ltd. July 4, 2014 Nivolumab Overview

What We Provide

Therapeutic Antibody

We provide high-quality for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Reference
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Nivolumab

** Information presented in the table were collected from the following websites:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554
https://www.ema.europa.eu/medicines/human/EPAR/opdivo
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=231868
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93204
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/4291427A1


For research use only. Not intended for any clinical use.

Send Inquiry

© 2021 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart